Abstract
Background: Glioblastoma is a malignant brain tumor with poor prognosis requiring early diagnosis. Secondary glioblastoma refers to cases that progressed from low-grade glioma. Evidence shows that timely resection correlates with increased survival.
Case presentation: We describe a case of a patient with secondary glioblastoma who was mistakenly diagnosed with Angiostrongylus cantonensis infection until 7 years after disease onset. The patient presented with non-specific clinical manifestations at disease onset. A conventional magnetic resonance imaging (MRI) in the primary survey provided insufficient information, and thus failed to identify the malignancy. During follow-up, unfortunately, clinicians were misled by the patient's raw food diet, a positive serum parasite antibody and a result of low glucose metabolism on Fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PET-CT). The patient was diagnosed with parasitosis. However, his condition kept getting worse under antiparasitic treatment. Preoperative magnetic resonance spectroscopy (MRS) and diffusion tensor imaging (DTI) failed to reverse the mistaken impression. Final diagnosis was confirmed until intraoperative and postoperative pathological findings indicated glioblastoma.
Conclusion: We ascribe the incorrect diagnosis to insufficient understanding on imaging manifestations of brain neoplasm as well as clinical features of parasitosis. Thus, we review the MRI, FDG-PET-CT, MRS, and DTI data of this case according to the timeline, refer to relevant studies, and point out the pitfalls. With a long course of slowly progressing, this was a rare case of secondary glioblastoma with the absence of isocitrate dehydrogenase 1 (IDH1) gene mutation.
Introduction
Glioblastoma is the most common type of malignant brain tumor. The overall survival of patients with glioblastoma is extremely poor, with a survival rate of 42.4% at 6 months, 17.7% at 1 year, and 3.3% at 2 years (). Secondary glioblastoma refers to cases that have progressed slowly from low-grade astrocytoma. According to the SEOM clinical guidelines of low-grade gliomas (LGGs) (), surgical resection is the first step when dealing with LGGs, and the overall patient survival is increased after a thorough resection. Thus, early diagnosis of gliomas is critical. Here, we report a case of secondary glioblastoma that was mistakenly diagnosed with Angiostrongylus cantonensis infection, which affected our ability to properly treat the patient.
Case Report
A 53-year-old male from southwestern China was admitted to our hospital on September 21, 2018 with a complaint of intermittent headaches for 7 years and right leg weakness for 6 months. The patient often consumed sashimi, raw oysters, bullfrogs, and snakes, and before the onset of the symptoms, he consumed raw beef. The patient had a long history of seeking medical help without significant alleviation of the major symptoms.
In March 2011, the patient presented with an intermittent headache that was largely confined to the cranial vertex. In November 2013, he underwent a magnetic resonance imaging (MRI) scan that was unremarkable, except for the presence of small patchy areas in the left frontal lobe (Figure 1). The patient was prescribed symptomatic drugs and his condition improved.
Figure 1
In October 2017, however, his headache returned, and the pain was more severe. He underwent another MRI scan, revealing a cystic lesion with rim enhancement at the same location (Figure 2).
Figure 2
Fluorodeoxyglucose-positron emission tomography-computed tomography (FDG-PET-CT) showed low metabolism (Figure 3), and coupled with the patient's raw food diet, a diagnosis of parasitosis was made. The patient was positive for A. cantonensis antibodies in the serum, but not in the cerebrospinal fluid. However, DNA test for A. cantonensis by polymerase chain reaction (PCR) was negative. The patient was prescribed albendazole, a broad-spectrum anthelmintic, and his condition improved after five courses. Unfortunately, he began to complain of right leg weakness. An MRI scan performed in March 2018 showed an enlarged cystic lesion in the left frontal lobe (figure not shown).
Figure 3
The diagnosis of parasitosis was confirmed at follow-up, and the patient was prescribed one course of praziquantel, which was ineffective. The headache worsened, and after 3 months, the patient was admitted to our hospital.
Upon admission, a physical examination showed weakness of the right leg, which was worse in the distal (0/5) than in the proximal (4/5) muscles, with an ipsilateral hyperactive knee reflex and positive Chaddock's sign. An MRI scan revealed further enlargement of the lesion (Figure 4), and magnetic resonance spectroscopy (MRS, Figure 5A) and diffusion tensor imaging (DTI, Figure 5B) were scheduled. MRS detected a significantly heightened choline (Cho) peak and a weakened N-acetylaspartate (NAA) peak. DTI showed an invasion into the left pyramidal tract.
Figure 4
Figure 5
We performed lesion resection under an intraoperative electrophysiological monitor to protect the adjoining precentral gyrus (Figure 6A). Swelling of the left frontal cortex, which was close to the midline, came into view as soon as the brain was exposed. Beneath the cortex, there was a solid-cystic lesion containing pale-yellow cystic fluid (Figure 6B). No scolex or larvae were seen. The cyst wall was soft and dark red in appearance (Figure 6C). The intraoperative report indicated high-grade glioma.
Figure 6
The postoperative pathological findings indicated glioma, classified as glioblastoma, WHO IV according to 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System. Histological analysis showed an absence of mutation of the isocitrate dehydrogenase 1 (IDH1) gene (Figure 7).
Figure 7
Written consent for publication of this case report was obtained from the patient.
Discussion
We describe a case of a patient with secondary glioblastoma who was mistakenly diagnosed with parasitosis and received inappropriate treatment. In view of the slow progression of the disease, an early diagnosis would have resulted in a better prognosis. There were several reasons for the incorrect diagnosis: inadequate attention to the initial abnormality on the MRI scan; insufficient knowledge on the clinical features of different parasitosis; and being misled by the patient's raw food diet, serological antigen positivity and FDG-PET results.
Initial MRI Results
The first MRI scan was conducted in 2013, ~2 years after the onset of disease. This scan showed an abnormal signal in the left frontal cortex that was barely discerned in the absence of enhancement.
Conventional MRI, which includes T2-weighted and pre- and post-gadolinium contrast-enhanced T1-weighted images, can provide sufficient anatomic details. It is often used in the diagnosis of brain tumors (, ). In the absence of cellular, metabolic and vascular information, however, it is difficult to differentiate neoplastic brain masses from non-neoplastic brain masses. Thus, physiology-based MRI methods, such as diffusion-weighted imaging (DWI), MRS, and perfusion-weighted imaging (PWI), are often used to increase the sensitivity and specificity of the detection (, ) and the grading () of brain tumors. Although the patient underwent DWI (Figure 2) in 2017, MRS (Figure 5A) in 2018, and DTI (Figure 5B) in 2018, all of which indicated glioblastoma, the opportunity for a timely and appropriate treatment has gone.
Al-Okaili et al. histologically confirmed the effectiveness of a multimode MRI-based approach () in differentiating intra-axial brain masses. Its accuracy, sensitivity, and specificity were 90, 97, and 67%, respectively, for the discrimination of neoplastic lesions from non-neoplastic lesions, and 90, 88, and 100%, respectively, for the discrimination of high-grade neoplasms from low-grade neoplasms. According to this strategy, MRS follows MRI to further differentiate an unenhanced intracerebral lesion. Low grade neoplasm or encephalitis are considered when there is elevation of Cho/NAA ratio over 2.2 in an unenhanced brain lesion. Even with the ratio <2.2, low-grade neoplasms cannot be excluded and further follow-up or biopsy is required.
In our case, the patient underwent only conventional MRI and was followed-up for the abnormal signal. Although this decision seemed reasonable at the time, we should have handled the case with higher vigilance and requested more frequent follow-ups, instead of a 4-year gap without re-examination.
Follow-Up MRI Results
The second MRI scan was conducted in 2017. The scan revealed a cystic lesion at the same region, which presented as a low signal on T1-weighted image, a high signal on T2/T2-FLAIR with surrounding edema, and a low signal on DWI. Post-contrast T1-weighted image revealed rim enhancement. A third MRI scan was conducted in 2018, and the image was identical to the scan from 2017, except that the lesion was further enlarged.
In general, gliomas are solid tumors with or without enhancement (). The formation of cyst raises the possibility of a high-grade glial neoplasm (). In the MRI scan in 2017, different from the typical enhancement features of glioblastoma, where there tend to be an irregular, garland-shaped rim (), the cyst was oval and had relatively smooth inner margin. Thus, it was challenging to differentiate it from benign lesions with similar manifestation. Cysticercosis, abscesses, and tuberculomas (, ) are among the most common ones.
Nevertheless, the DWI provided us with critical information. Previous studies (–) have revealed that DWI can differentiate cystic intracerebral lesions. Both high-grade gliomas and metastases are hypointense on DWI scans and can reveal high diffusion on Apparent diffusion coefficient (ADC) maps () as a result of facilitated diffusion. On the contrary, abscesses () usually appear with limited diffusion and are hyperintense on DWI scans. With regard to the MRI-based approach (), an enhanced lesion with facilitated diffusion should have been diagnosed as a high-grade neoplasm.
At the time of diagnosis, however, the patient's special diet, relative atypical enhancement pattern and PET-CT results were misleading, and the MRI results were mistaken for cystic parasitosis with central necrosis. It must be noted that liquefactive necrotic area can also exhibit hypointense lesions on DWI with increased ADC, reflecting the process of encephalomalacia with unrestricted water motion (), but rim enhancement is hardly the feature of A. cantonensis infection, as discussed blow.
MRS revealed a heightened Cho peak and a weakened NAA peak, with a Cho/NAA ratio of 4.9. The level of Cho/NAA ratio helps distinguish different grades of glioma (). It is significantly higher in HGGs (3.86 ± 3.31) and lower in LGGs (0.81 ± 0.90) (). Following an established diagnosis of high-grade neoplasm based on MRI, a Cho/NAA ratio over 1 in peri-enhancement area leads to the diagnosis of high-grade glioma ().
A DTI scan, which helped us to understand the relationship between the tumor and the ipsilateral pyramidal tract, was performed 9 days before the surgery. DTI is based on diffusion measurements, and its parameters (i.e., apparent diffusion coefficient [ADC], mean diffusivity [MD], and fractional anisotropy [FA]) reflect the integrity of the white matter and tumor infiltration (, ). Due to differences in these characteristics, both LGGs and high grade gliomas (HGGs) (), as well as HGGs and brain metastases (), can be discriminated. An arithmetic formula combining multiple parameters can achieve a sensitivity of 91.7% and a specificity of 86.4% when differentiating LGGs from metastases (), as well as a sensitivity of 84.8%, a specificity of 74.5%, and an accuracy of 80.4% when differentiating HGGs from LGGs ().
We measured the FA value in the non-enhancing tumor core, edematous brain, and contralateral normal white matter (Figure 8) and found that the distribution was consistent with that of earlier studies on HGGs. The non-enhancing tumor core had the lowest FA value, and the normal white matter had the highest ().
Figure 8
FDG-PET Results
A PET-CT scan was conducted in October 2017, <1 month after the second MRI scan. The report revealed “decreased glucose metabolism, consistent with a primary benign lesion.” Combined with the patient's history of eating raw meat and the positive serological findings, clinicians arrived at an incorrect diagnosis, which affected the treatment protocol.
Low-grade gliomas tend to exhibit low uptake of glucose, whereas high-grade gliomas tend to exhibit high uptake of FDG compared with normal gray and white matter (, ). Based on the MRI scan from 2017, we considered a high-grade tumor and deemed the PET-CT results as unreasonable.
Studies have reported that FDG-PET can reveal hypo- or iso-metabolism in high-grade gliomas (, ). The fact that normal brain tissue has the highest glucose metabolic rate in the body implies the intrinsic shortage of glucose-metabolism-based FDG-PET in the detection of intracerebral tumors.
New non-FDG tracers for PET-CT are available. Amino acid based tracers, such as [11C]methionine ([11C]MET) (, ) and [18F]fluoroethyl-L-tyrosine ([18F]FET) (), are ideal imaging biomarkers of tumor growth, since they are rarely up-taken by cells in the normal brain but accumulate in proliferating cells as a result of up-regulated protein synthesis.
According to a previous study, FET sensitivity was 93%, specificity 100%, accuracy 96%, positive predictive value (PPV) 100% and negative predictive value (NPV) 91% for detecting malignant brain tumors, while FDG sensitivity was 27%, specificity 90%, accuracy 52%, PPV 80%, and NPV 45%(). Other studies (, ) also revealed a significantly better performance of FET compared to FDG-PET in the detection of brain tumors. In addition, a previous study revealed that brain lesions showing hypo- or iso-metabolism on FDG-PET can be detected and differentiated with high sensitivity using MET-PET (). Taking all these into consideration, we would have arrived at a different diagnosis if amino acid-based PET was used instead of, or in addition to, FDG-PET alone.
Personal History and Serological Results
The patient's history of eating raw meat led the attending physician to screen for a parasitic infection.
Most cases of cerebral parasitosis derive from cerebral cysticercosis, whose imaging features are variable (, ). Solitary parenchymal cyst (SCC) (, ) is one of its most common manifestations, with an incidence of approximately 23.59% (). Degenerating cysts can appear as single contrast-enhancing rings surrounded by edema, which could be confused with gliomas (, ).
However, it is important to point out that the serological results indicated the presence of A. cantonensis IgG instead of cysticercosis. A. cantonensis infects humans through third-stage larvae from snails, slugs, or contaminated, uncooked vegetables (, ). The typical manifestation of A. cantonensis infection is eosinophilic meningitis (, ). It can present as a disc lesion after the formation of an abscess (), but a brain abscess exhibits distinct features in DWI, as we discussed above. In this case, there was no evidence of meningitis, no increase in serum or CSF eosinophils, and the PCR results were negative for A. cantonensis infection, which was inconsistent with the serological results. PCR, as a molecular approach that can detect a single molecule of DNA, has a better sensitivity in detecting parasites than morphological and biological techniques (, ). Thus, it was very likely that the patient was not infected with A. cantonensis.
The pathological findings confirmed the diagnosis of glioblastoma, which is classified as WHO IV according to 2016 World Health Organization (WHO) Classification of Tumors of the Central Nervous System (). Based on clinical manifestations, this case was typical of secondary glioblastoma, with neuroimaging evidence of an evolution from a less malignant astrocytoma (). According to a previous population-based study (), this type of glioma is very rare, accounting for only 5.3% of all glioblastomas. By contrast, primary or de-novo glioblastomas, which manifest rapidly (clinical history is <3 months in the majority of cases) without radiological or histological evidence of a less malignant precursor lesion, account for 94.7% of all glioblastomas. Our patient was 46 years old at disease onset, which is close to the mean onset age (i.e., 45 years) of secondary glioblastoma, whereas primary glioblastomas develop in older patients, with a mean age of 62 years ().
What is remarkable is that, despite a clinical slow-growing feature, the tumor turned out to be IDH-wildtype, which is a minority in secondary glioblastomas and might imply a distinct histological origin () from the majority.
The patient underwent normative resection and complementary treatment immediately after confirmation of the pathology. We also arrived at several important considerations after all these twists and turns.
Firstly, early stage malignant gliomas can manifest neither specific clinical signs such as epileptic seizure or focal neurological deficits, nor imaging signs of necrosis or significant enhancement (). A comprehensive imaging protocol, one that involves multi-parametric MRI, is necessary and efficient when dealing with undefined cerebral lesions.
Secondly, a low glucose metabolism is not always indicative of a benign lesion. It is critical for clinicians to recognize the limitations of FDG-PET in cerebral imaging.
Thirdly, when trying to make a diagnosis of a rare disease, such as brain A. cantonensis infection, it is important to fully understanding its manifestations and carefully gather clues.
Last but not least, consecutive follow-ups are indispensable in such cases. A comparative research in 2012 proved that early resection of LGGs was associated with better overall survival compared to the “biopsy and watchful waiting” strategy (). Supposing that the patient in our case had more frequent follow-up and early biopsy, an early diagnosis and resection could be possible. As malignant neoplasm can have subtle imaging appearances in early stage, clinicians should always be vigilant.
Statements
Data availability statement
All datasets generated for this study are included in the manuscript/supplementary files.
Author contributions
CL: collected and analyzed patient information and wrote the manuscript. WX: performed the surgery. PL: analyzed and rebuilt DTI. YW: performed the surgery and reviewed the manuscript.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
References
1.
OhgakiHDessenPJourdeBHorstmannSNishikawaTDi PatrePLet al. Genetic pathways to glioblastoma: a population-based study. Cancer Res. (2004) 64:6892–9. 10.1158/0008-5472.CAN-04-1337
2.
Sepulveda-SanchezJMMunoz LangaJArraezMAFusterJHernandez LainAReynesGet al. SEOM clinical guideline of diagnosis and management of low-grade glioma (2017). Clin Transl Oncol. (2018) 20:3–15. 10.1007/s12094-017-1790-3
3.
FelixRSchornerWLaniadoMNiendorfHPClaussenCFieglerWet al. Brain tumors: MR imaging with gadolinium-DTPA. Radiology. (1985) 156:681–8. 10.1148/radiology.156.3.4040643
4.
Brant-ZawadzkiMBadamiJPMillsCMNormanDNewtonTH. Primary intracranial tumor imaging: a comparison of magnetic resonance and CT. Radiology. (1984) 150:435–40. 10.1148/radiology.150.2.6691098
5.
HouraniRBrantLJRizkTWeingartJDBarkerPBHorskaA. Can proton MR spectroscopic and perfusion imaging differentiate between neoplastic and nonneoplastic brain lesions in adults?AJNR Am J Neuroradiol. (2008) 29:366–72. 10.3174/ajnr.A0810
6.
PivawerGLawMZagzagD. Perfusion MR imaging and proton MR spectroscopic imaging in differentiating necrotizing cerebritis from glioblastoma multiforme. Magn Reson Imaging. (2007) 25:238–43. 10.1016/j.mri.2006.09.028
7.
LawMYangSWangHBabbJSJohnsonGChaSet al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol. (2003) 24:1989–98.
8.
Al-OkailiRNKrejzaJWooJHWolfRLO'RourkeDMJudyKDet al. Intraaxial brain masses: MR imaging-based diagnostic strategy–initial experience. Radiology. (2007) 243:539–50. 10.1148/radiol.2432060493
9.
ScottJNBrasherPMSevickRJRewcastleNBForsythPA. How often are nonenhancing supratentorial gliomas malignant? A population study. Neurology. (2002) 59:947–9. 10.1212/WNL.59.6.947
10.
DeanBLDrayerBPBirdCRFlomRAHodakJACoonsSWet al. Gliomas: classification with MR imaging. Radiology. (1990) 174:411–5. 10.1148/radiology.174.2.2153310
11.
TaillibertSLe RhunEChamberlainMC. Intracranial cystic lesions: a review. Curr Neurol Neurosci Rep. (2014) 14:481. 10.1007/s11910-014-0481-5
12.
ShettyGAvabrathaKSRaiBS. Ring-enhancing lesions in the brain: a diagnostic dilemma. Iran J Child Neurol. (2014) 8:61–4. 10.22037/ijcn.v8i3.5296
13.
OsbornAGPreeceMT. Intracranial cysts: radiologic-pathologic correlation and imaging approach. Radiology. (2006) 239:650–64. 10.1148/radiol.2393050823
14.
ReddyJSMishraAMBehariSHusainMGuptaVRastogiMet al. The role of diffusion-weighted imaging in the differential diagnosis of intracranial cystic mass lesions: a report of 147 lesions. Surg Neurol. (2006) 66:246–50; discussion 250–1. 10.1016/j.surneu.2006.03.032
15.
ReicheWSchuchardtVHagenTIl'yasovKABillmannPWeberJ. Differential diagnosis of intracranial ring enhancing cystic mass lesions–role of diffusion-weighted imaging (DWI) and diffusion-tensor imaging (DTI). Clin Neurol Neurosurg. (2010) 112:218–25. 10.1016/j.clineuro.2009.11.016
16.
EbisuTTanakaCUmedaMKitamuraMNaruseSHiguchiTet al. Discrimination of brain abscess from necrotic or cystic tumors by diffusion-weighted echo planar imaging. Magn Reson Imaging. (1996) 14:1113–6. 10.1016/S0730-725X(96)00237-8
17.
MishraAMGuptaRKJaggiRSReddyJSJhaDKHusainNet al. Role of diffusion-weighted imaging and in vivo proton magnetic resonance spectroscopy in the differential diagnosis of ring-enhancing intracranial cystic mass lesions. J Comput Assist Tomogr. (2004) 28:540–7. 10.1097/00004728-200407000-00017
18.
ChoiSNohDKimYJeongIChoiHLeeYet al. Magnetic resonance imaging characteristics of ischemic brain infarction over time in a canine stroke model. J Vet Sci. (2018) 19:137–42. 10.4142/jvs.2018.19.1.137
19.
WangQZhangHZhangJWuCZhuWLiFet al. The diagnostic performance of magnetic resonance spectroscopy in differentiating high-from low-grade gliomas: a systematic review and meta-analysis. Eur Radiol. (2016) 26:2670–84. 10.1007/s00330-015-4046-z
20.
TongTYangZChenJWZhuJYaoZ. Dynamic 1H-MRS assessment of brain tumors: a novel approach for differential diagnosis of glioma. Oncotarget. (2015) 6:32257–65. 10.18632/oncotarget.4899
21.
WhiteMLZhangYYuFJaffar KazmiSA. Diffusion tensor MR imaging of cerebral gliomas: evaluating fractional anisotropy characteristics. AJNR Am J Neuroradiol. (2011) 32:374–81. 10.3174/ajnr.A2267
22.
PriceSJBurnetNGDonovanTGreenHAPenaAAntounNMet al. Diffusion tensor imaging of brain tumours at 3T: a potential tool for assessing white matter tract invasion?Clin Radiol. (2003) 58:455–62. 10.1016/S0009-9260(03)00115-6
23.
KaoHWChiangSWChungHWTsaiFYChenCY. Advanced MR imaging of gliomas: an update. Biomed Res Int. (2013) 2013:970586. 10.1155/2013/970586
24.
JiangRDuFZHeCGuMKeZWLiJH. The value of diffusion tensor imaging in differentiating high-grade gliomas from brain metastases: a systematic review and meta-analysis. PLoS ONE. (2014) 9:e112550. 10.1371/journal.pone.0112550
25.
HoefnagelsFWDe Witt HamerPSanz-ArigitaEIdemaSKuijerJPPouwelsPJet al. Differentiation of edema and glioma infiltration: proposal of a DTI-based probability map. J Neurooncol. (2014) 120:187–98. 10.1007/s11060-014-1544-9
26.
InanoROishiNKuniedaTArakawaYYamaoYShibataSet al. Voxel-based clustered imaging by multiparameter diffusion tensor images for glioma grading. Neuroimage Clin. (2014) 5: p. 396–407. 10.1016/j.nicl.2014.08.001
27.
SinhaSBastinMEWhittleIRWardlawJM. Diffusion tensor MR imaging of high-grade cerebral gliomas. AJNR Am J Neuroradiol. (2002) 23:520–7.
28.
DerlonJMPetit-TaboueMCChaponFBeaudouinVNoelMHCreveuilCet al. The in vivo metabolic pattern of low-grade brain gliomas: a positron emission tomographic study using 18F-fluorodeoxyglucose and 11C-L-methylmethionine. Neurosurgery. (1997) 40:276–87; discussion 287–8. 10.1097/00006123-199702000-00009
29.
TamuraMShibasakiTZamaAKuriharaHHorikoshiSOnoNet al. Assessment of malignancy of glioma by positron emission tomography with 18F-fluorodeoxyglucose and single photon emission computed tomography with thallium-201 chloride. Neuroradiology. (1998) 40:210–5. 10.1007/s002340050569
30.
YoonJHKimJHKangWJSohnCHChoiSHYunTJet al. Grading of cerebral glioma with multiparametric MR imaging and 18F-FDG-PET: concordance and accuracy. Eur Radiol. (2014) 24:380–9. 10.1007/s00330-013-3019-3
31.
ChungJKKimYKKimSKLeeYJPaekSYeoJSet al. Usefulness of 11C-methionine PET in the evaluation of brain lesions that are hypo- or isometabolic on 18F-FDG PET. Eur J Nucl Med Mol Imaging. (2002) 29:176–82. 10.1007/s00259-001-0690-4
32.
UllrichRTKrachtLBrunnAHerholzKFrommoltPMileticHet al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients with glioma. J Nucl Med. (2009) 50:1962–8. 10.2967/jnumed.109.065904
33.
KinoshitaMGotoTAritaHOkitaYIsohashiKKagawaNet al. Imaging (1)(8)F-fluorodeoxy glucose/(1)(1)C-methionine uptake decoupling for identification of tumor cell infiltration in peritumoral brain edema. J Neurooncol. (2012) 106:417–25. 10.1007/s11060-011-0688-0
34.
WeberWAWesterHJGrosuALHerzMDzewasBFeldmannHJet al. O-(2-[18F]fluoroethyl)-L-tyrosine and L-[methyl-11C]methionine uptake in brain tumours: initial results of a comparative study. Eur J Nucl Med. (2000) 27:542–9. 10.1007/s002590050541
35.
LauEWDrummondKJWareREDrummondEHoggARyanGet al. Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumour. J Clin Neurosci. (2010) 17:43–9. 10.1016/j.jocn.2009.05.009
36.
PlotkinMBlechschmidtCAufGNyuykiFGeworskiLDeneckeTet al. Comparison of F-18 FET-PET with F-18 FDG-PET for biopsy planning of non-contrast-enhancing gliomas. Eur Radiol. (2010) 20:2496–502. 10.1007/s00330-010-1819-2
37.
NatafVKerrouKBalogovaSPeneFHuchetVGutmanFet al. [Fluoroethylthyrosine 18F PET in the detection of brain tumours]. Bull Cancer. (2010) 97:495–506. 10.1684/bdc.2010.1078
38.
LernerAShiroishiMSZeeCSLawMGoJL. Imaging of neurocysticercosis. Neuroimaging Clin N Am. (2012) 22:659–76. 10.1016/j.nic.2012.05.004
39.
ChawlaSHusainNKumarSPalLTripathiMGuptaRK. Correlative MR imaging and histopathology in porcine neurocysticercosis. J Magn Reson Imaging. (2004) 20:208–15. 10.1002/jmri.20105
40.
RajshekharVChandyMJ. Validation of diagnostic criteria for solitary cerebral cysticercus granuloma in patients presenting with seizures. Acta Neurol Scand. (1997) 96:76–81. 10.1111/j.1600-0404.1997.tb00243.x
41.
RajashekharV. Solitary cerebral cysticercus granuloma. Epilepsia. (2003) 44 (Suppl. 1):25–8. 10.1046/j.1528-1157.44.s.1.10.x
42.
WangZLFuTXHuYXLiGLMaoDHTanWB. [Comparative study on EEG and neuroimaging of patients with cerebral cysticercosis before and after treatment]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. (2014) 26:311–9.
43.
SilverSAErozanYSHrubanRH. Cerebral cysticercosis mimicking malignant glioma: a case report. Acta Cytol. (1996) 40:351–7. 10.1159/000333767
44.
MittalASehgalRSurekaBKumarAAggarwalKC. Giant cerebral cysticercosis in an infant confused with a thalamic glioma. J Child Neurol. (2014) 29:154–6. 10.1177/0883073813513332
45.
PienFDPienBC. Angiostrongylus cantonensis eosinophilic meningitis. Int J Infect Dis. (1999) 3:161–3. 10.1016/S1201-9712(99)90039-5
46.
DengJZouJXZhouXMWuZD. [A review of researches on Angiostrongylus cantonensis and angiostrongyliasis cantonensis: analysis of related literatures]. Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. (2012) 24:228–31.
47.
LvSZhouXNAndrewsJR. Eosinophilic meningitis caused by angiostrongylus cantonensis. ACS Chem Neurosci. (2017) 8:1815–6. 10.1021/acschemneuro.7b00233
48.
MaMZhangMQiuZ. Eosinophilic meningitis caused by Angiostrongylus cantonensis in an infant: a case report. Medicine. (2018) 97:e10975. 10.1097/MD.0000000000010975
49.
PurohitAKDinakarISundaramCRatnakarKS. Angiostrongylus cantonensis abscess in the brain. J Neurol Neurosurg Psychiatry. (1991) 54:1015–6. 10.1136/jnnp.54.11.1015-a
50.
ZarlengaDSHigginsJ. PCR as a diagnostic and quantitative technique in veterinary parasitology. Vet Parasitol. (2001) 101:215–30. 10.1016/S0304-4017(01)00568-4
51.
MalouNRaoultD. Immuno-PCR: a promising ultrasensitive diagnostic method to detect antigens and antibodies. Trends Microbiol. (2011) 19:295–302. 10.1016/j.tim.2011.03.004
52.
LouisDNPerryAReifenbergerGvon DeimlingAFigarella-BrangerDCaveneeWKet al. The 2016 World Health Organization classification of tumors of the central nervous system: a summary. Acta Neuropathol. (2016) 131:803–20. 10.1007/s00401-016-1545-1
53.
OhgakiHKleihuesP. Genetic pathways to primary and secondary glioblastoma. Am J Pathol. (2007) 170:1445–53. 10.2353/ajpath.2007.070011
54.
OhgakiHKleihuesP. The definition of primary and secondary glioblastoma. Clin Cancer Res. (2013) 19:764–72. 10.1158/1078-0432.CCR-12-3002
55.
RossiRFigusACorraineS. Early presentation of de novo high grade glioma with epileptic seizures: electroclinical and neuroimaging findings. Seizure. (2010) 19:470–4. 10.1016/j.seizure.2010.07.001
56.
JakolaASMyrmelKSKlosterRTorpSHLindalSUnsgardGet al. Comparison of a strategy favoring early surgical resection vs a strategy favoring watchful waiting in low-grade gliomas. JAMA. (2012) 308:1881–8. 10.1001/jama.2012.12807
Summary
Keywords
secondary glioblastoma, brain neoplasm, parasitosis, mistaken diagnosis, multi-parametric MRI, FDG-PET, FET-PET
Citation
Liu C, Xu W, Liu P and Wei Y (2019) A Mistaken Diagnosis of Secondary Glioblastoma as Parasitosis. Front. Neurol. 10:952. doi: 10.3389/fneur.2019.00952
Received
14 June 2019
Accepted
20 August 2019
Published
06 September 2019
Volume
10 - 2019
Edited by
David D. Eisenstat, University of Alberta, Canada
Reviewed by
Randy Jensen, The University of Utah, United States; Brad E. Zacharia, Penn State Milton S. Hershey Medical Center, United States
Updates
Copyright
© 2019 Liu, Xu, Liu and Wei.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Yukui Wei weiyukui74@163.com
This article was submitted to Neuro-Oncology and Neurosurgical Oncology, a section of the journal Frontiers in Neurology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.